Lomaira and Belviq XR Are New C-IV Meds for Weight Loss

January 2017

Please see the February 2020 FDA recommendation to remove Belviq and Belviq XR from the market.

Lomaira and Belviq XR will offer new options for weight loss.

Lomaira (loh-MER-uh) is a "low-dose" version of phentermine. It contains phentermine 8 mg...instead of 15, 30, or 37.5 mg.

Expect most patients on Lomaira to take up to one tab three times daily 30 minutes before meals...instead of once or twice daily like higher-strength phentermine products.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

OTC Products Help Patients Prevent Overdoses and Mix-Ups With OTCs
Insurance Prioritize Urgent Prior Auth Requests to Avoid Gaps in Therapy
Diabetes Adlyxin and Soliqua Join a Crowded Market of Injectable Diabetes Meds
End-of-Life Care Help With Unique End-of-Life Med Considerations
Obesity & Weight Loss Lomaira and Belviq XR Are New C-IV Meds for Weight Loss
Opioids Be Ready to Help More Patients Use Buprenorphine/Naloxone for Opioid Dependence
Calcium Send Patients With Questions About Calcium Supplements to the Pharmacist
Acne Help Patients Use New OTC Differin 0.1% Acne Gel Safely
Vaccines Expect Pregnant Women to Get Tdap Vaccine With Every Pregnancy
Dehydration Help Sort Through Options for Managing Dehydration in Kids
Inhalers Help Prevent Common Inhaler Errors

Lomaira and Belviq XR Are New C-IV Meds for Weight Loss

Practical advice for a better career, with unlimited access to CE

Table of Contents